Stock analysts at Daiwa Capital Markets began coverage on shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in a research report issued on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the stock.
Several other brokerages have also weighed in on JNJ. Credit Suisse Group increased their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Morgan Stanley lowered their price target on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Finally, Raymond James raised their price target on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $190.50.
JNJ stock opened at $179.66 on Wednesday. The firm has a market capitalization of $472.76 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 3.42 and a beta of 0.66. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The business has a 50 day simple moving average of $177.65 and a 200-day simple moving average of $173.20.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,161 shares of company stock worth $13,895,302. Insiders own 0.35% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. RB Capital Management LLC increased its position in shares of Johnson & Johnson by 1.8% during the first quarter. RB Capital Management LLC now owns 9,626 shares of the company’s stock worth $1,706,000 after purchasing an additional 169 shares in the last quarter. Ulland Investment Advisors LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $296,000. Castle Rock Wealth Management LLC increased its position in shares of Johnson & Johnson by 3.9% during the fourth quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock worth $2,119,000 after purchasing an additional 479 shares in the last quarter. Bennett Selby Investments LP increased its position in shares of Johnson & Johnson by 1.9% during the first quarter. Bennett Selby Investments LP now owns 16,899 shares of the company’s stock worth $2,995,000 after purchasing an additional 308 shares in the last quarter. Finally, Rehmann Capital Advisory Group increased its position in shares of Johnson & Johnson by 3.2% during the fourth quarter. Rehmann Capital Advisory Group now owns 43,045 shares of the company’s stock worth $7,364,000 after purchasing an additional 1,348 shares in the last quarter. Institutional investors own 68.78% of the company’s stock.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.